Henry I. Miller

Robert Wesson Fellow in Scientific Philosophy and Public Policy

Henry I. Miller, MS, MD, is the Robert Wesson Fellow in Scientific Philosophy and Public Policy at the Hoover Institution. His research focuses on public policy toward science and technology, encompassing a number of areas, including pharmaceutical development, genetic engineering in agriculture, models for regulatory reform, and the emergence of new viral diseases.

Miller served for fifteen years at the US Food and Drug Administration (FDA) in a number of posts. He was the medical reviewer for the first genetically engineered drugs to be evaluated by the FDA and thus instrumental in the rapid licensing of human insulin and human growth hormone. Thereafter, he was a special assistant to the FDA commissioner and the founding director of the FDA's Office of Biotechnology. During his government service, Miller participated frequently on various expert and policy panels as a representative of the FDA or the US government. As a government official, Miller received numerous awards and citations.

Since coming to the Hoover Institution, Miller has become well known not only for his contributions to scholarly journals but also for his articles and books that make science, medicine, and technology accessible. His work has been widely published in many languages. Monographs include Policy Controversy in Biotechnology: An Insider's View; To America's Health: A Model for Reform of the Food and Drug Administration; and The Frankenfood Myth: How Protest and Politics Threaten the Biotech Revolution. Barron's selected The Frankenfood Myth as one of the 25 Best Books of 2004. In addition, Miller has published extensively in a wide spectrum of scholarly journals and popular publications worldwide, including The Lancet, Journal of the American Medical Association, Science, the Nature family of journals, Chronicle of Higher Education, Forbes, National Review, Wall Street Journal, New York Times, the Guardian, Defining Ideas, and the Financial Times. He is a regulator contributor to Forbes.com and frequently appears on the nationally syndicated radio programs of John Batchelor and Lars Larson.

Miller was selected by the editors of Nature Biotechnology as one of the people who had made the "most significant contributions" to biotechnology during the previous decade. He serves on numerous editorial boards.

Filter By:



Recent Commentary

Analysis and Commentary

Congress Can Make Regulators Accountable

by Henry I. Miller, Jeff Stiervia National Review
Thursday, March 23, 2017

And the FDA would be a good place to start.


Cancer Prevention, Occurrence And Treatment: A Game Of Probabilities

by Joel E. Tepper, Henry I. Millervia Forbes
Wednesday, March 22, 2017

"The Prevent-Cancer Diet!” “A New Molecular Target for Treating Pancreatic Cancer!” We are constantly bombarded with media announcements of miraculous breakthroughs, giving the false impression that cancer is well on the way to being eliminated as a serious threat, but non-experts–including most reporters–often fail to understand that the improvements are not like the Salk polio vaccine virtually wiping out a dread disease almost overnight.

Analysis and Commentary

On ‘Right To Try,’ The FDA Should Proceed With Caution

by Henry I. Millervia Wall Street Journal
Monday, March 13, 2017

More access to unapproved drugs could be good policy, but there are risks even to terminal patients.

Analysis and Commentary

Great Mentors Ease The Way Over Life's Rough Spots

by Henry I. Millervia Forbes
Wednesday, March 8, 2017

CNN last year ran a series of vignettes about the network's anchors and correspondents with the theme, “The Person Who Changed My Life.” It got me thinking about two people who had a profound effect in setting me on the path of my life's professional journey.

Analysis and Commentary

Politics-Related Depression: Is It Real?

by Mia Zaharna, Henry I. Millervia National Review
Friday, March 3, 2017

Fragile types in liberal enclaves have a hard time coping with Trump’s election.

Analysis and Commentary

NGO-Driven EPA Regulations Based On Bad Science Need Reform

by Henry I. Millervia The Hill
Wednesday, March 1, 2017

With all its warts, the Trump administration has hit the ground running on pulling back regulatory overreach. The president has issued a pair of critical, wide-ranging executive orders — one that requires federal agencies to revoke two regulations for every new rule they want to issue, and another that requires the cost of any additional regulations to be completely offset by undoing existing rules.

Analysis and Commentary

Michelle Obama And Chef Tom Colicchio Form A Misguided Partnership

by Henry I. Miller, Jeff Stiervia Forbes
Wednesday, February 22, 2017

Just when many of us hoped that we would soon be seeing the last of the Obamas, it appears that Michelle Obama will still be involved in what passes for public service in progressives’ parallel universe. She has decided to partner with the far left-wing Food Policy Action Education Fund, a sister organization of the radical Food Policy Action.

Analysis and Commentary

It’s Time To Shine A Light On Regulatory 'Dark Matter'

by Angela Logomasini, Henry I. Millervia National Review
Monday, February 20, 2017

President Donald Trump’s desire to shrink the regulatory state by significantly cutting the number of regulations and their impact is laudable. But it won’t be easy, and it won’t be sufficient, because the federal bureaucracy’s tentacles reach deep into private enterprise through a number of non-regulatory programs and actions that if left in place will continue to hinder economic growth.


Will Genetically Engineered Animals Finally Bring Home The Bacon?

by Henry I. Millervia Forbes
Wednesday, February 15, 2017

It’s unusual for an obscure procedural federal law to attract much attention, especially if it’s 20 years old, but the Congressional Review Act is creating buzz. A game-changer for regulatory reform, it could be a significant stimulus to job creation and economic growth.

Blank Section (Placeholder)Analysis and Commentary

Can Trump Make Bureaucrats Accountable?

by Henry I. Millervia Defining Ideas
Friday, February 10, 2017

Officials deserve protection, but not when they undermine the public interest.